Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The National Institute for Heath and Care Excellence (NICE) today recommended two treatments for eye disorders for use on the NHS in England and Wales.
NICE, which provides guidance on the cost-effectiveness of treatments for NHS use, published final guidance backing both a new indication for Novartis' eye drug Lucentis (ranibizumab) and Alimera Sciences' intravitreal implant Iluvien (fluocinolone acetonide).
The Lucentis guidance covers the use of the medicine to treat sight problems caused by choroidal neovascularisation (CNV) in people with a rare form of short-sightedness known as pathological myopia.
http://www.pmlive.com/pharma_news/nice_backs_two_eye_treatments_522173
NICE, which provides guidance on the cost-effectiveness of treatments for NHS use, published final guidance backing both a new indication for Novartis' eye drug Lucentis (ranibizumab) and Alimera Sciences' intravitreal implant Iluvien (fluocinolone acetonide).
The Lucentis guidance covers the use of the medicine to treat sight problems caused by choroidal neovascularisation (CNV) in people with a rare form of short-sightedness known as pathological myopia.
http://www.pmlive.com/pharma_news/nice_backs_two_eye_treatments_522173